On November 8, 2024 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET will be presented at the SITC (Free SITC Whitepaper) Annual Meeting 2024 (Press release, Innate Pharma, NOV 8, 2024, View Source [SID1234648054]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to share our latest preclinical data at the SITC (Free SITC Whitepaper) Annual Meeting, highlighting the potential of IPH6501, our tetra-specific NK cell engager and IPH4502, our innovative ADC targeting Nectin-4. These findings underscore our commitment to advancing next-generation immunotherapies and reflect significant progress in the development of our drug candidates. We look forward to engaging with the scientific community as we continue to push the boundaries of next generation immunotherapies," commented Pr. Eric Vivier, Chief Scientific Officer of Innate Pharma.
Details of the presentations
Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting | 6-10 November, Houston, Texas and Virtual
Harnessing NK Cells in Cancer Therapies
Session 107d: NK Cells and Innate Immunity
Presentation Type: Oral Presentation
Session Date and Time: Friday, Nov. 8, 2024, 3:50-5:25pm CST
Presentation Time: 4:35pm CST
Speaker: Eric Vivier, Chief Scientific Officer, Innate Pharma (co-chair of the session)
Preclinical Characterization of IPH6501: A Novel IL2v-Armed Tetraspecific NK Cell Engager Targeting CD20 in Relapsed or Refractory B cell Non-Hodgkin Lymphoma Subtypes and Post-CAR-T Therapy.
Abstract Number: 1083
Presentation Type: Poster Presentation
Primary Category: Immuno-Conjugates and Chimeric Molecules
Poster Presentation Day: Friday, Nov. 8, 2024
IPH45, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4
Abstract Number: 1056
Presentation Type: Poster Presentation
Primary Category: Immuno-Conjugates and Chimeric Molecules
Poster Presentation Day: Saturday, Nov. 9, 2024
More information can be found on the JITC website.
Protein & Antibody Engineering Summit (PEGS) Europe | November 5-7, Barcelona, Spain and virtual
In addition, the presentation entitled « A Next-Generation ADC for Nectin-4 Expressing Tumours: Preclinical Characterisation of IPH45, a Novel and Differentiated Exatecan-Based ADC Targeting Nectin-4 » was presented at the PEGS Europe Summit. The presentation is available on the Company website, in the publications section.
About IPH4502
IPH4502 is a novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.
In non-clinical models, IPH4502 is well tolerated and shows anti-tumor efficacy in vitro and in vivo.
In September 2024, the U.S Food and Drug Administration cleared Innate’s investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502 in Nectin-4 expressing solid tumor indications.
About IPH6501
IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not a subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells.
IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA (Free EHA Whitepaper) 2023).
IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.